IND for iCo

iCo Therapeutics, an Isis Pharmaceuticals licensee, has filed an Investigational New Drug (IND) application with the FDA for iCo-007.

iCo Therapeutics, an Isis Pharmaceuticals licensee, has filed an Investigational New Drug (IND) application with the FDA for iCo-007.

iCo-007, for the treatment of eye diseases such as age-related macular degeneration and diabetic retinopathy, is a second generation drug that inhibits the production of c-Raf kinase, an enzyme associated with the development of new blood vessels in the eye.

Isis will receive a milestone payment from iCo based on the IND filing.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.